Drug Database
DE

desloratadine + pseudoephedrine (Clarinex D / Aerinaze)

✓ Approved

Merck & Co. · HRH1 · 小分子

什么是 desloratadine + pseudoephedrine?

desloratadine + pseudoephedrine 是一种小分子,由Merck & Co.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Clarinex D, Aerinaze
公司Merck & Co.
药物类别小分子
分子靶点HRH1
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

desloratadine + pseudoephedrine 作用于 1 个分子靶点:

HRH1histamine receptor H1 (HH1R, H1R)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

desloratadine + pseudoephedrine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Immune system disordersSeasonal allergy✓ Approved

相关研究文献

PubMedNorthern clinics of Istanbul2026-11-17

Systemic peptide inhibitor of transendothelial migration administration attenuates microvascular leukocyte adhesion in an ovalbumin-induced mouse model of allergic inflammation.

Sevim Mustafa M, Akbaba Alperen A, Yerli Doganay D, Sulu Ela E et al.

Allergic rhinitis (AR) is driven by type 2 immune polarization and excessive leukocyte trafficking. Current pharmacotherapies act symptomatically rather than at the level of transendothelial migration (TEM). Peptide inhibitor of TEM (PEPITEM) is a B lymphocyte-derived peptide that engages endothelial cadherin-15 to stimulate sphingosine-1-phosphate secretion and inhibit lymphocyte firm adhesion. Although effective in Type 1 autoimmune and metabolic inflammation, PEPITEM has not been examined in Type 2 allergic disease. To evaluate whether systemic PEPITEM administration attenuates systemic leukocyte trafficking in an ovalbumin (OVA)-induced murine AR model, using desloratadine as a clinically established comparator. Thirty-two C57Bl/6 mice (16 males, 16 females; 10-12 weeks; 20-25 g) were randomized to four groups (n=4 per sex per group): control, allergy, allergy+desloratadine (10 mg/kg oral gavage), and allergy+PEPITEM (200 μg/200 μL intraperitoneal). AR was induced by intraperitoneal OVA/alum sensitization (days 1-13) and intranasal 1% OVA challenge (days 22-25). Leukocyte rolling counts, stationary, and adherent leukocytes in mesenteric post-capillary venules were quantified by intravital microscopy (IVM). Peripheral leukocyte differentials were determined by hemogram. One-way analysis of variance was used as the primary analysis. OVA sensitization and challenge increased peripheral lymphocytosis (p=0.0446-0.0059) and eosinophilia (p=0.0019) and significantly elevated stationary leukocytes and adhesion (p=0.0003) in mesenteric venules, while rolling was statistically unchanged. PEPITEM reduced firmly adherent leukocyte density (p<0.05 vs. allergy group) and normalized blood eosinophilia, with effects comparable to those observed in the desloratadine-treated group. Tissue oxidative and inflammatory marker analysis showed limited organ-specific changes; PEPITEM reduced myeloperoxidase activity in the liver (p=0.0158) and colon (p=0.0288), whereas malondialdehyde and glutathione levels were largely unchanged across tissues. In this study, systemic PEPITEM administration reduces systemic leukocyte adhesion and several allergic phenotypes during OVA-driven Type 2 inflammation, with effects of similar magnitude to desloratadine.

PMID 43041745
阅读全文 →
PubMedOrganic letters2026-11-13

Self-Photocatalyzed Difluoromethylation-Cyclization and Controllable Hydrodefluorination: Access to Medium-Sized Monofluoro-N-heterocycles.

Sun Lianglong L, Sun Kai K, Dong Qinghao Q, Shi Tongtong T et al.

Molecular editing enabling precision hydrodefluorination remains a highly challenging endeavor owing to the high C-F bond energy and the possibility of exhaustive defluorination. At present, the established strategy for hydrodefluorination is mainly dedicated to specific C-F bonds, including trifluoromethylarenes, trifluoroacetates, and amides. Herein, we present an energy-mediated self-photocatalyzed intramolecular difluoromethylation-cyclization and controllable hydrodefluorination protocol to medium-sized monofluoro-N-heterocycles. Broad substrate scope and functional group compatibility, biologically active molecule modification (Erlotinib, Norethisterone, Norgestrel, Norquetiapine, Desloratadine, Melatonin, Vortioxetine, and Ethynyl Estradiol), large-scale synthesis, and diverse derivatization highlight the utility of this catalytic strategy.

PMID 43023912
阅读全文 →
PubMedChemistry (Weinheim an der Bergstrasse, Germany)2026-11-05

Total Synthesis and Absolute Configuration of the Irregular Tetraterpene Viaticene A.

Stamm Patrick P, Solak Ozan O, Kuhn Johanna J, Schulz Stefan S

Viaticenes are tetraterpenes with a unique [6+2]-connectivity known from the epicuticular lipid layer of the springtail Hypogastrura viatica. Here, we report the total synthesis of viaticene A in thirteen steps from methyl 5-hexynoate, with an overall yield of 16%. Key steps in the construction of the core fragment include the stereoselective introduction of the E- and Z-double bonds via silyl- and carbocupration, respectively, and establishment of the central stereogenic center using pseudoephedrine as a chiral auxiliary. Subsequently, C9- and C11-alkyl building blocks are coupled to the core fragment via copper-mediated allylic substitution and nickel/cobalt-cocatalyzed vinyl-alkyl cross-electrophile coupling, preventing double-bond migration in the latter reaction with the novel additive combination styrene/water/molecular sieves. The modular synthesis route gives selective access to relevant diastereomers, allowing determination of the absolute configuration of viaticene A. Configurations at C-3, C-7, and C-19 are elucidated through careful analysis of the 13C-NMR spectra, assigning the all-R-configuration to the natural product.

PMID 42983587
阅读全文 →
PubMedJournal of visualized experiments : JoVE2026-10-31

Combination Therapy of Montelukast and Desloratadine in Pediatric Allergic Rhinitis: Effects on Symptoms and Inflammatory Markers.

Wang Jingfeng J, Huang Dongdong D, Cai Zhang Z, Lin Qiming Q

This retrospective, controlled study evaluated the clinical outcomes of montelukast sodium combined with desloratadine syrup in pediatric patients with allergic rhinitis. Medical records from 360 children aged 6-12 years treated between October 2021 and November 2024 were reviewed. Patients were classified according to documented treatment as desloratadine monotherapy (Group A, n = 180) or desloratadine plus montelukast (Group B, n = 180). During the 4-week treatment period, Total Nasal Symptom Score (TNSS), Total Non-Nasal Symptom Score (TNNSS), time to symptom improvement, serum immunoglobulin E (IgE), interleukin-13 (IL-13), eosinophil counts, and adverse events were assessed. Group B had lower post-treatment TNSS (4.65 ± 2.12 vs 5.32 ± 2.09, p = 0.003) and TNNSS (1.96 ± 1.43 vs 2.48 ± 1.01, p < 0.001), and rhinorrhea improved sooner (10.38 ± 1.87 vs 13.48 ± 1.20 days, p < 0.001). Greater reductions were also observed in inflammatory markers, including IgE and IL-13 (90.36 ± 22.58 vs 102.78 ± 19.25 ng/L, p < 0.001). Adverse-event rates did not differ significantly (0.56% vs 1.67%; Fisher's exact test, p = 0.623), although only four events were recorded. These findings indicate that combination therapy was associated with greater improvements in clinical symptoms and inflammatory markers than desloratadine monotherapy; however, the retrospective, nonrandomized design and limited safety events require cautious interpretation.

PMID 42965351
阅读全文 →
PubMedBMC chemistry2026-10-22

Eco-sustainable organic solvent-free spectrophotometric method for the concurrent determination of a ternary pharmaceutical mixture.

Hamdy Abdallah M AM, Meselhy Esraa M EM, El Henawee Magda M MM, Hashem Hisham H et al.

In recent years, green analytical chemistry has become essential in pharmaceutical research, aiming to mitigate environmental hazards associated with conventional analytical practices. The current focus lies in optimizing analytical methods to achieve both environmental and economic sustainability. In this framework, three environmentally sustainable spectrophotometric methods were developed for simultaneous analysis of three co-formulated drugs: acetaminophen, dextromethorphan hydrobromide, and pseudoephedrine hydrochloride, which are often used to alleviate symptoms associated with COVID-19. The employed spectrophotometric methodologies include the double divisor-ratio spectra derivative method, the mean centering of double divisor ratio spectra method, and the dual wavelength in ratio spectrum method. The innovative techniques displayed good linearity within 25-350 µg/mL for dextromethorphan hydrobromide, 2-24 µg/mL for acetaminophen, and 100-1400 µg/mL for pseudoephedrine hydrochloride. The environmental sustainability of the proposed methods was evaluated using the Analytical Eco-Scale, analytical greenness metric, and the Green Analytical Procedure Index. Furthermore, complementary evaluations of blueness and whiteness were conducted through the Blue Applicability Grade Index and the Red Green Blue 12 metric, respectively. The collective outcomes of all evaluation metrics clearly demonstrated that the proposed methods possess enhanced environmental compatibility and sustainability relative to the existing techniques. The proposed methods were fully validated according to the International Conference on Harmonization recommendations. The developed methods offered a cost-effective and eco-friendly approach for concurrent determination of acetaminophen, dextromethorphan hydrobromide, and pseudoephedrine hydrochloride in their bulk substances, and pharmaceutical formulations.

PMID 42907898
阅读全文 →
PubMedSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026-10-19

Association between prophylactic desloratadine use and docetaxel-induced skin toxicities in patients with early-stage breast cancer: an inverse probability-weighted retrospective cohort study.

Makihara Katsuya K, Kongo Keisuke K, Motomura Kayo K, Kimoto Daiki D et al.

Docetaxel (DTX) causes skin toxicities despite dexamethasone-based supportive care, and no established adjunctive primary prophylaxis exists. We assessed whether desloratadine, a peripheral H1-receptor antagonist with anti-inflammatory properties, was associated with DTX-related skin toxicities in early-stage breast cancer. This single-center retrospective cohort included 143 patients with stage I-III breast cancer receiving perioperative DTX-based chemotherapy (75 mg/m2 every 3 weeks) with dexamethasone premedication. Desloratadine (5 mg daily from the morning after first DTX infusion through treatment completion) was prescribed nonrandomly to 49 patients (34.3%); 94 received no prophylactic antihistamine. The primary outcome was any patient-reported skin toxicity (rash, pruritus, or hand-foot syndrome [HFS]). The primary analysis used Hájek-normalized stabilized inverse probability of treatment weighting (IPTW), with 95% confidence intervals (CIs) from 2,000 patient-level bootstrap resamples with propensity-score refitting. Calendar-time confounding was assessed by post-implementation restriction. After stabilized IPTW, skin-toxicity incidence was 46.2% with desloratadine and 70.7% without it (risk difference, - 24.6 percentage points; 95% CI, - 43.0 to - 5.3; risk ratio [RR], 0.65; 95% CI, 0.42-0.92). Descriptive estimates indicated lower pruritus incidence (RR, 0.36; 95% CI, 0.08-0.79), a lower but imprecise rash estimate (RR, 0.70; 95% CI, 0.43-1.03), and no lower HFS incidence (5.9% vs 5.4%). Post-implementation findings were similar (RR, 0.61; 95% CI, 0.42-0.90); negative-control neuropathy was not lower (RR, 1.19; 95% CI, 0.52-2.58). Desloratadine prophylaxis was associated with lower skin-toxicity risk, particularly for pruritus. Rash risk was lower but imprecisely estimated; HFS risk was not lower. These hypothesis-generating findings warrant validation in a prospective randomized trial.

PMID 42895563
阅读全文 →

注册免费账户还可查看另外 2318 篇文献

免费注册查看全部文献 →

了解更多desloratadine + pseudoephedrine